ArticleJournal of analytical toxicology2020
Blood Concentrations of Designer Benzodiazepines: Relation to Impairment and Findings in Forensic Cases.
Article in Journal of analytical toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Forensic toxicology of benzodiazepines: neuropharmacological effects, analytical challenges, and emerging detection strategies.Frontiers in toxicology · 2025Review
- The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases.Journal of analytical toxicology · 2023Review
- Interpol review of toxicology 2019-2022.Forensic science international. Synergy · 2023Review
- Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.Neurology international · 2022Review
- Etizolam Blood Concentrations in 191 Forensic Cases in Ontario, Canada (2019-2020).Journal of analytical toxicology · 2022Article
- The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.Toxicology research · 2022Article
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.Journal of analytical toxicology · 2022Review
- The blood-to-plasma ratio and predicted GABAForensic toxicology · 2022Article
- A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues.Forensic toxicology · 2022Article
- Recent findings and advancements in the detection of designer benzodiazepines: a brief review.Arhiv za higijenu rada i toksikologiju · 2022Review
- Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Benzodiazepines reported in NFLIS-Drug, 2015 to 2018.Forensic science international. Synergy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of designer benzodiazepines appears to be increasing in many countries, but data concerning blood concentrations are scarce, making interpretation of concentrations difficult. The aim of this study was to report blood concentrations of clonazolam, diclazepam, etizolam, flualprazolam, flubromazepam, flubromazolam and phenazepam and to investigate the relationship between blood concentrations and impairment. The concentration data are from blood samples collected from living cases (apprehended drivers and other drug offences) and medico-legal autopsies. The blood samples were analysed for the seven designer benzodiazepines mentioned above by ultra high performance liquid chromatography-tandem mass spectrometry. Positive cases from between 1 June 2016 and 30 September 2019 were included. Blood concentrations and the conclusion from a clinical test of impairment (when available) are reported. The presented seven benzodiazepines were detected in a total of 575 cases, where 554 of these cases concerned apprehended drivers or other criminal offenders. The number of findings and the median (range) concentrations were as follows: clonazolam, n = 22, 0.0041 mg/L (0.0017-0.053 mg/L); diclazepam, n = 334, 0.0096 mg/L (0.0016-0.25 mg/L); etizolam, n = 40, 0.054 mg/L (0.015-0.30 mg/L); flualprazolam, n = 10, 0.0080 mg/L (0.0033-0.056 mg/L); flubromazepam, n = 5, 0.037 mg/L (0.0070-0.70 mg/L); flubromazolam, n = 20, 0.0056 mg/L (0.0004-0.036 mg/L); and phenazepam, n = 138, 0.022 mg/L (0.0018-0.85 mg/L). A designer benzodiazepine was the only drug detected with relevance for impairment in 25 of the 554 living cases. The physician concluded with impairment in 19 of the 25 cases. Most of the concentrations in these cases were relatively similar to or higher than the median reported concentrations. The most frequent other drugs detected were amphetamine, tetrahydrocannabinol, clonazepam and methamphetamine. The presented blood concentrations can be helpful with the interpretation of cases involving one or more of these seven benzodiazepines. The results indicate that concentrations commonly observed in forensic cases are associated with impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.